Lupus
Richard Conway RichardPAConway
3 years 3 months ago
Morand et al Tyk2i deucravacitinib in SLE. 48-week phase 2 RCT. SRI(4) PBO: 34.4%; DEUC 3 mg BID: 58.2%, P =0.0006; DEUC 6 mg BID: 49.5%, P =0.021; DEUC 12 mg QD: 44.9%, P =0.078. BICLA, LLDAS, CLASI-50, active joint count also+ @RheumNow #EULAR2022 LB0004 https://t.co/MBPc9xQFvG https://t.co/n3GUwl0RtD
Eric Dein ericdeinmd
3 years 3 months ago
PAISLEY LB004
@EricFMorand on deucravacitinib phase 2 for SLE
⭐️Meets primary endpt: SRI(4)
⭐️Secondary endpts: BICLA, LLD, CLASI, jt count, biomarkers improved
⭐️Safety data wo VTE, CVD events
Earlier at #EULAR2022, BRAVE trial phase 3 baricitinib: No benefit in SLE
@RheumNow https://t.co/3YpPSJcenF
Aurelie Najm AurelieRheumo
3 years 3 months ago
PAISLEY study Phase 2 RCT
Deucravacitinib in SLE meets primary endpoint wk 32
Results for dose 3mg BID:
*SRI(4) response 58.2% vs.
PBO 34%
*LLDAS 36%
*CLASI 70%
*⬇️ SJC
No new safety signal
Now waiting for Phase 3 👀
@RheumNow LB0004 #EULAR2022 #Lupus https://t.co/2KYSvfq4h7
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 3 months ago
Please see my video interview with Dr @LucyCarter6 on her prize winning #EULAR2022 abstract #OP0234 on transcriptomic analyses of peripheral bloods in identifying modules that predict OR protect progression from ANA+ to #lupus or CTD @RheumNow https://t.co/c3khwFzx79
Dr. John Cush RheumNow
3 years 3 months ago
Video: What Patients Want and Are Willing to Risk with SLE
Dr. Kathryn Dao discusses abstract POS0086 at #EULAR2022 which looks at real life lupus patient preferences who are willing to undergo risk in order to get the treatment outcome that they desire.
https://t.co/kHZz5MrZi2 https://t.co/XRsoXHR1ce
Janet Pope Janetbirdope
3 years 3 months ago
WIN-Lupus is no winner. Stopping #MMF or #Azathioprine after 2 to 3 yrs of well controlled #SLE is a loser due to more #lupus nephritis. Diff from RCT of MMF taper in remission pts. @RheumNow @eular_org #EULAR2022 https://t.co/Ut8uRonrNP
David Liew drdavidliew
3 years 3 months ago
So what diet to follow with autoimmunity in mind?
So many, all with different instructions.
Let’s concentrate on where they agree:
yes to fruits & vegetables
no to emulsifiers & processed foods
#EULAR2022 @RheumNow https://t.co/I9abweQOyZ
By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around! PAnd congrats to you virtual Rheums for mastering the multi-screen, multitask simultaneous consumption posters, tweets and oral abstract presentations.
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 3 months ago
#OP0279 #EULAR2022 Let's start with N=5! Promising new therapy CAR T-cell in #lupus. All patients were refractory to various therapies and had active nephritis. Post-treatment, all responded clinically and serologically! Need to go to RCT next @RheumNow https://t.co/RaTlVALQqn
Dr. John Cush RheumNow
3 years 3 months ago
Watch: AURORA-2 Two-year Results Voclosporin For Lupus Nephritis
https://t.co/k61KOBXRSl
#EULAR2022 https://t.co/Q7cjqvQyFG
ARD & RMD Open ARD_BMJ
3 years 3 months ago
Pharmacodynamic effect of sequential #belimumab and #rituximab therapy in patients with systemic #lupus: BLISS-BELIEVE study
#EULAR2022
>CR https://t.co/AgBBuqYatW
Richard Conway RichardPAConway
3 years 3 months ago
WIN-Lupus. RCT of stopping treatment in SLE. All on HCQ. Randomised to stop Aza/MMF after being stable on for 2-3 years. Relapse proliferative nephritis in 25% vs 10%. Severe SLE flare 32% vs 13%. @RheumNow #EULAR2022 OP0280 https://t.co/IAcCoKw1YI
Richard Conway RichardPAConway
3 years 3 months ago
Teng et al BLISS-BELIEVE Biomarker outcome RCT Sequential belimumab-rituximab in SLE. Certainly appears to be a serologic benefit on dsDNA, C3/4. But we need clinical parameters to correlate with this. @RheumNow #EULAR2022 OP0281 https://t.co/iEeSN0SNcr https://t.co/HN8ya4QZLU
Poster Hall